Search

everythinglearnresearchcommunity

for

Search:↓

Laser and light therapies, especially the 308 nm excimer laser, are effective and safe for treating alopecia areata, but more research is needed.

Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.

People who get alopecia areata after age 50 usually have mild symptoms, high chances of hair regrowth, and often have other health conditions.

Treatments for autoimmune hair loss have limited success and often relapse, and emotional support is crucial for those affected.

Oral vitamin D treatment can help some children with alopecia areata who have vitamin D deficiency.

Treatments for autoimmune hair loss have limited success and patients need emotional support and self-acceptance.

Antioxidants can help improve hair growth in people with alopecia areata.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Alopecia areata cases in children are rising, especially in females and low-income regions, with a projected increase in China and decrease in the USA.

Intralesional steroids improve Alopecia Areata, and trichoscopy effectively tracks this improvement.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Treating gum disease and stress may help improve alopecia.

Baricitinib successfully treated severe hair loss.

Alopecia areata is common in young males and linked to stress.

Early and proper treatment is crucial for children with allergic conjunctivitis to avoid complications.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Skin grafts on mice can cause an immune response leading to hair loss, useful for studying human hair loss conditions.

Tofacitinib may help treat severe hair loss, but more research is needed.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.

Alopecia areata treatment varies, with no optimal method established yet.

Trichoscopy helps diagnose and monitor alopecia areata by looking at a combination of specific hair and scalp features.

Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.